<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04524650</url>
  </required_header>
  <id_info>
    <org_study_id>PLAEGV-DIA</org_study_id>
    <nct_id>NCT04524650</nct_id>
  </id_info>
  <brief_title>Early Diagnosis of Oxaliplatin-induced Portal Hypertension</brief_title>
  <official_title>Construction and Evaluation of the Early Identification for Oxaliplatin Induced Portal Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oxaliplatin has been used as the first choice for the adjuvant chemotherapy of colorectal&#xD;
      cancer and it has significantly improved the outcomes in patients with colorectal cancer.&#xD;
      However, hepatotoxicity is the potentially problematic adverse effect of oxaliplatin. The&#xD;
      pathological evaluation of non-tumoral liver from patients with advanced colorectal cancer&#xD;
      undergoing neoadjuvant oxaliplatin-based treatment has provided histological evidence of&#xD;
      hepatic sinusoidal injury. Oxaliplatin-induced sinusoidal injury can persist for more than 1&#xD;
      year after the completion of chemotherapy, and the increase in splenic volume may be a&#xD;
      predictor of irreversible sinusoidal damage. In this current study, the investigators aim to&#xD;
      evaluate the values of potential biomarkers in diagnosing patients with oxaliplatin-induced&#xD;
      gastroesophageal varices after colorectal cancer surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 31, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the severity of portal hypertension</measure>
    <time_frame>1 day (the same time as diagnosis)</time_frame>
    <description>High portal pressure</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">370</enrollment>
  <condition>Gastroesophageal Varices</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Received Oxaliplatin-based Chemotherapy</condition>
  <arm_group>
    <arm_group_label>stage 0</arm_group_label>
    <description>without liver function injury or splenomegaly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>stage 1</arm_group_label>
    <description>occurrence of liver function injury (ALT or AST &gt; 2 ULN (upper limit of normal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>stage 2</arm_group_label>
    <description>occurrence of splenomegaly or reduced platelet count (&lt;150 X10^9/L)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>stage 3</arm_group_label>
    <description>occurrence of portal hypertension and/or gastroesophageal varices</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>the level of vWF</intervention_name>
    <description>the peripheral level of vWF</description>
    <arm_group_label>stage 0</arm_group_label>
    <arm_group_label>stage 1</arm_group_label>
    <arm_group_label>stage 2</arm_group_label>
    <arm_group_label>stage 3</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who had a history of colorectal cancer and received oxaliplatin-based chemotherapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients aged 18-75&#xD;
&#xD;
          -  Had a history of oxaliplatin-based chemotherapy for the treatment of colorectal cancer&#xD;
             surgery;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Combined known etiologies of chronic liver disease, including hepatitis, primary&#xD;
             biliary cirrhosis, schistosomiasis, and non-alcoholic fatty liver disease.&#xD;
&#xD;
          -  With colorectal cancer required further anti-tumor treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaoquan HUANG</last_name>
    <phone>008618801733835</phone>
    <email>huang.xiaoquan@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Gastroenterology and Hepatology</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Huang X, Li F, Wang L, Xiao M, Ni L, Jiang S, Ji Y, Zhang C, Zhang W, Wang J, Chen S. Endoscopic treatment of gastroesophageal variceal bleeding after oxaliplatin-based chemotherapy in patients with colorectal cancer. Endoscopy. 2020 Sep;52(9):727-735. doi: 10.1055/a-1157-8611. Epub 2020 May 7.</citation>
    <PMID>32380558</PMID>
  </results_reference>
  <results_reference>
    <citation>Aloia T, Sebagh M, Plasse M, Karam V, LÃ©vi F, Giacchetti S, Azoulay D, Bismuth H, Castaing D, Adam R. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006 Nov 1;24(31):4983-90.</citation>
    <PMID>17075116</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 20, 2020</study_first_submitted>
  <study_first_submitted_qc>August 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2020</study_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Shiyao Chen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>portal hypertension</keyword>
  <keyword>splenomegaly</keyword>
  <keyword>colorectal carcinoma</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>hepatotoxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

